CBS 2019
CBSMD教育中心
English

科学研究

科研文章

荐读文献

Multivessel Versus Culprit-Vessel Percutaneous Coronary Intervention in Cardiogenic Shock Mode of Death in Heart Failure With Preserved Ejection Fraction Routine Continuous Electrocardiographic Monitoring Following Percutaneous Coronary Interventions Switching P2Y12-receptor inhibitors in patients with coronary artery disease The spectrum of chronic coronary syndromes: genetics, imaging, and management after PCI and CABG 稳定性冠心病诊断与治疗指南 Macrophage MST1/2 Disruption Impairs Post-Infarction Cardiac Repair via LTB4 Burden of 30-Day Readmissions After Percutaneous Coronary Intervention in 833,344 Patients in the United States: Predictors, Causes, and Cost 2019 ESC Guidelines for the management of patients with supraventricular tachycardia The Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC): Developed in collaboration with the Association for European Paediatric and Congenital Cardiology (AEPC)he management of patients with) Current Smoking and Prognosis After Acute ST-Segment Elevation Myocardial Infarction: New Pathophysiological Insights

Original Research2021 Mar 22.

JOURNAL:J Proteome Res. Article Link

Metabolic Interactions and Differences between Coronary Heart Disease and Diabetes Mellitus: A Pilot Study on Biomarker Determination and Pathogenesis

WP Liu, PF Guo, T Dai Keywords: diabetes coronary heart disease metabolomics metabolism

ABSTRACT

Comprehensive understanding of plasma metabotype of diabetes mellitus (DM), coronary heart disease (CHD), and especially diabetes mellitus with coronary heart disease (CHDDM) is still lacking. In this work, the plasma metabolic differences and links of DM, CHD, and CHDDM patients were investigated by the strategy of comparative metabolomics based on 1H NMR spectroscopy combined with network analysis for revealing their metabolic differences. A total of 17 metabolites are related to three diseases, among which valine, alanine, leucine, isoleucine, and N-acetyl-glycoprotein are positively correlated with CHD and CHDDM (odds ratios (OR) > 1). The trimethylamine oxide, glycerol, lactose, indoleacetate, and scyllo-inositol are closely related to the development of DM to CHDDM (OR > 1), and indoleactate (OR: 1.06, 95% confidence interval (CI): 1.01–1.12) and lactose (OR: 2.46, 95% CI: 1.67–3.25) are particularly prominent in CHDDM. We identified three multi-biomarkers types that were significantly associated with glycosylated hemoglobin (HbA1C) at baseline. All diseases demonstrated dysregulated glycolysis/gluconeogenesis and amino acid biosynthesis pathway. In addition, enrichment in tryptophan metabolism observed in CHDDM, enrichment in inositol phosphate metabolism observed in DM, and the metabolites related to microbiota metabolism were dysregulated in both DM and CHDDM. The comparative metabolomics strategy of multi-diseases offers a new perspective in disease-specific markers and pathogenic pathways.